search
Back to results

Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease (CKD), Not on Dialysis

Primary Purpose

Anemia

Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Roxadustat
Placebo
Sponsored by
AstraZeneca
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Anemia focused on measuring Renal,, CKD,, Roxadustat,, anemia,, non-dialysis

Eligibility Criteria

18 Years - 130 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Provision of informed consent prior to any study specific procedures.
  2. Age ≥18 years at screening visit 1
  3. eGFR <60 mL/min/1.73 m2, (calculated by central lab) corresponding to stage 3, 4 or 5CKD according to the Kidney Disease Outcomes Quality Initiative (KDOQI), not receiving dialysis
  4. Mean of 2 most recent central laboratory Hb values during the screening period, obtained at least 7 days apart, must be <10.0 g/dL
  5. Ferritin ≥50 ng/mL at randomization (obtained from screening visit)
  6. TSAT ≥15 % at randomization (obtained from screening visit)
  7. Serum folate level ≥ lower limit of normal (LLN) at randomization (obtained from screening visit)
  8. Serum vitamin B12 level ≥LLN at randomization (obtained from screening visit)
  9. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3 x upper limit of normal (ULN) and total bilirubin (Tbili) ≤1.5 x ULN at randomization (obtained from screening visit)
  10. Body weight 45 to 160 kg

Exclusion Criteria:

  1. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site)
  2. Previous randomization in the present study
  3. Any erythropoietin analogue treatment within 6 weeks of randomization
  4. New York Heart Association Class III or IV congestive heart failure at enrollment
  5. Myocardial infarction (MI), acute coronary syndrome, stroke, seizure or a thrombotic/thromboembolic event (e.g., deep vein thrombosis or pulmonary embolism) within 12 weeks prior to randomization
  6. History of chronic liver disease (e.g., chronic infectious hepatitis, chronic auto- immune liver disease, cirrhosis or fibrosis of the liver)
  7. Known hereditary hematologic disease such as thalassemia, sickle cell anemia, a history of pure red cell aplasia or other known causes for anemia other than CKD
  8. Known and untreated retinal vein occlusion or known and untreated proliferative diabetic retinopathy (risk for retinal vein thrombosis)
  9. Diagnosis or suspicion (e.g. complex kidney cyst of Bosniak Category IIF, III or IV) of renal cell carcinoma on renal ultrasound (or other imaging procedure e.g. CT scan or MRI) conducted at screening or within 12 weeks prior to randomization
  10. Systolic BP ≥160 mmHg or diastolic BP ≥95 mmHg (confirmed by repeated measurement), within 2 weeks prior to randomization. Patients may be rescreened once BP controlled
  11. History of prostate cancer, breast cancer or any other malignancy, except the following: cancers determined to be cured or in remission for ≥5 years, curatively resected basal cell or squamous cell skin cancers, cervical cancer in situ, or resected colonic polyps
  12. Positive for any of the following: human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) or anti-hepatitis C virus antibody (anti-HCV Ab)
  13. Chronic inflammatory diseases such as rheumatoid arthritis, systemic lupus erythematosus (SLE), ankylosing spondylitis, psoriatic arthritis or inflammatory bowel disease that is determined to be the principal cause of anemia
  14. Known hemosiderosis, hemochromatosis or hypercoagulable condition
  15. Any prior organ transplant or a scheduled organ transplantation date
  16. Any red blood cell transfusion (RBC) during the screening period
  17. Any current condition leading to active significant blood loss
  18. Any treatment with roxadustat or a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI)
  19. Has received another new chemical entity (defined as a compound which has not been approved for marketing) or has participated in any other clinical study that included drug treatment within at least 1 month of the first administration of IP in this study. (Note: patients consented and screened, but not randomized in this study or a previous study are not excluded)
  20. History of alcohol or drug abuse within 2 years prior to randomization
  21. Females of childbearing potential, unless using contraception as detailed in the protocol or sexual abstinence
  22. Pregnant or breastfeeding females
  23. Known allergy to the investigational product or any of its ingredients
  24. Any medical condition, including active, clinically significant infection, that in the opinion of the investigator or Sponsor may pose a safety risk to a patient in this study, which may confound efficacy or safety assessment or may interfere with study participation

Sites / Locations

  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Roxadustat

Placebo

Arm Description

Outcomes

Primary Outcome Measures

Mean Change From Baseline in Hb Averaged Over Week 28 to Week 52
Baseline Hb was defined as the mean of the last 3 central laboratory Hb values from the screening and randomization visits. Mean change in Hb from baseline to mean value from Week 28 to Week 52 was analyzed using a missing at random (MAR) based multiple imputation analysis of covariance (ANCOVA) model with baseline Hb, baseline estimated glomerular filtration rate (eGFR), cardiovascular (CV) history, geographic region and treatment group as fixed effect covariates. The adjusted least squares (LS) mean estimates of change from baseline to mean during Week 28 to Week 52 are presented.

Secondary Outcome Measures

Percentage of Participants With Hb Response During the First 24 Weeks of Treatment
Hb response was defined as: Hb ≥ 11.0 g/dL and Hb increase from baseline by ≥ 1.0 g/dL for participants with baseline Hb > 8.0 g/dL; or Hb increase from baseline by ≥ 2.0 g/dL, for participants with baseline Hb ≤ 8.0 g/dL at 2 consecutive visits (with available data) separated at least 5 days during the first 24 weeks of treatment without having received rescue therapy (red blood cell [RBC] transfusion, erythropoietin analogue, or intravenous [IV] iron) prior to Hb response. The percentage of participants with an Hb response during the first 24 weeks of treatment is presented.
Mean Change From Baseline in Hb Averaged Over Week 28 to Week 52 in Participants With Baseline High Sensitivity C-Reactive Protein (hsCRP) Greater Than the Upper Limit of Normal (ULN)
Baseline hsCRP was quantified from stored biomarker samples obtained at randomization. Baseline Hb was defined as the mean of the last 3 central laboratory Hb values from the screening and randomization visits. Mean change in Hb from baseline to mean value during Week 28 to Week 52 was analyzed using a MAR based multiple imputation ANCOVA model with baseline Hb, baseline eGFR, CV history, geographic region and treatment group as fixed effect covariates. The adjusted LS mean estimates of change from baseline in participants with baseline hsCRP >ULN to mean during Week 28 to Week 52 are presented.
Proportion of Total Time of Interpolated Hb Values Greater Than or Equal To 10 g/dL From Week 28 to Week 52
Proportion of total time of interpolated Hb values ≥10 g/dL was calculated as the time the linearly interpolated curve between measurements ≥10 g/dL divided by the time between measurements from Week 28 to Week 52. Proportion of total time was analyzed using an ANCOVA model with baseline Hb and baseline eGFR as covariates, and CV history, geographic region and treatment group as fixed effects. The adjusted LS mean estimates of change from Week 28 to Week 52 are presented.
Proportion of Total Time of Interpolated Hb Values Within the Interval of 10 to 12 g/dL From Week 28 to Week 52
Proportion of total time of interpolated Hb values within the interval of 10 to 12 g/dL was calculated as the time the linearly interpolated curve between measurements were within 10 to 12 g/dL divided by the time between measurements from Week 28 to Week 52. Proportion of total time was analyzed using an ANCOVA model with baseline Hb and baseline eGFR as covariates, and CV history, geographic region and treatment group as fixed effects. The adjusted LS mean estimates of change from Week 28 to Week 52 are presented.
Mean Change in Low-Density Lipoprotein (LDL) Cholesterol From Baseline to Week 24
Baseline LDL was defined as the last result obtained prior to randomization. Mean changes in LDL cholesterol from baseline to Week 24 was analyzed using an ANCOVA model with baseline LDL, baseline Hb and baseline eGFR as covariates, and CV history, geographic region and treatment group as fixed effects. The adjusted LS mean estimates of change from baseline to Week 24 are presented.
Time-To-First Instance of Receiving IV Iron, RBC Transfusion or Erythropoietin Analogue as Rescue Therapy
Time-to-first rescue therapy (IV iron, RBC transfusion or erythropoietin analogue) was calculated as (date of first rescue therapy, or date of censoring if no rescue therapy was taken) minus (date of first dose of IP) +1. Event rate was calculated as (number of participants with event) divided by (the total number of days at risk for event across all participants in given group divided by 365.25) multiplied by 100. The event rate is presented for participants with events.
Time-To-First Instance of Receiving a RBC Transfusion As Rescue Therapy
Time-to-first RBC rescue therapy was calculated as (date of first RBC rescue therapy, or date of censoring if no rescue therapy was taken) minus (date of first dose of IP) +1. Event rate was calculated as (number of participants with event) divided by (the total number of days at risk for event across all participants in given group divided by 365.25) multiplied by 100. The event rate is presented for participants with events.
Mean Change From Baseline in Short Form 36 (SF-36) Vitality Sub-Score From Week 12 to Week 28
SF-36 is a Quality of Life (QoL) scale comprising 8 domains of health status: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role Emotional and Mental Health. Each domain score is on a scale from 0-100 (worst health possible to best health possible); higher scores indicate better health status. Mean change in SF-36 Vitality sub-score from baseline to mean from Week 12 to Week 28 was analyzed using a mixed model for repeated measures (MMRM) with terms for baseline score, treatment group, baseline Hb, baseline eGFR, CV history, geographic region, visit and treatment-by-visit interaction as fixed effects and participant as random effect. The adjusted LS mean estimates of change from baseline to mean score from Week 12 to Week 28 are presented.
Annual Rate of eGFR Change From Baseline Prior to the Initiation of Dialysis or Kidney Transplant
Baseline eGFR was defined as the mean of all available central laboratory values prior to or at randomization. Rate of change in eGFR from baseline during the entire treatment period (in millilitres/minute/1.73 meters squared/years [mL/min/1.73m^2/years]) was estimated using a random effects model using all post-baseline eGFR values prior to initiation of dialysis/transplant. Baseline eGFR, baseline Hb, geographic region, CV history, treatment group and post-baseline eGFR measurement time were used as fixed effects and participant and time (years) as random effects, ie, random intercept and slope.
Mean Change From Baseline in SF-36 Physical Functioning Sub-Score From Week 12 to Week 28
SF-36 is a QoL scale comprising 8 domains of health status: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role Emotional and Mental Health. Each domain score is on a scale from 0-100 (worst health possible to best health possible); higher scores indicate better health status. Mean change in SF-36 Physical Functioning sub-score from baseline to mean from Week 12 to Week 28 was analyzed using a MMRM with terms for baseline score, treatment group, baseline Hb, baseline eGFR, CV history, geographic region, visit and treatment-by-visit interaction as fixed effects and participant as random effect. The adjusted LS mean estimates of change from baseline to mean score from Week 12 to Week 28 are presented.

Full Information

First Posted
June 24, 2014
Last Updated
November 27, 2019
Sponsor
AstraZeneca
Collaborators
FibroGen
search

1. Study Identification

Unique Protocol Identification Number
NCT02174627
Brief Title
Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease (CKD), Not on Dialysis
Official Title
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Roxadustat for the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis
Study Type
Interventional

2. Study Status

Record Verification Date
November 2019
Overall Recruitment Status
Completed
Study Start Date
June 26, 2014 (Actual)
Primary Completion Date
October 4, 2018 (Actual)
Study Completion Date
October 4, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
AstraZeneca
Collaborators
FibroGen

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of the study is to evaluate the safety and efficacy of roxadustat for treatment of anemia in patients with chronic kidney disease not on dialysis
Detailed Description
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study in anemic patients with Stage 3, 4 or 5 chronic kidney disease (CKD) who are not on dialysis.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Anemia
Keywords
Renal,, CKD,, Roxadustat,, anemia,, non-dialysis

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
2781 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Roxadustat
Arm Type
Experimental
Arm Title
Placebo
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
Roxadustat
Intervention Description
The initial study drug dose is 70 mg three times a week (TIW). The dose is subsequently adjusted to achieve and maintain Hb 11±1 g/dL.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
The initial study drug dose is 70 mg three times a week (TIW). The dose is subsequently adjusted to achieve and maintain Hb 11±1 g/dL.
Primary Outcome Measure Information:
Title
Mean Change From Baseline in Hb Averaged Over Week 28 to Week 52
Description
Baseline Hb was defined as the mean of the last 3 central laboratory Hb values from the screening and randomization visits. Mean change in Hb from baseline to mean value from Week 28 to Week 52 was analyzed using a missing at random (MAR) based multiple imputation analysis of covariance (ANCOVA) model with baseline Hb, baseline estimated glomerular filtration rate (eGFR), cardiovascular (CV) history, geographic region and treatment group as fixed effect covariates. The adjusted least squares (LS) mean estimates of change from baseline to mean during Week 28 to Week 52 are presented.
Time Frame
Baseline (Day 1, Week 0) and Week 28 to Week 52.
Secondary Outcome Measure Information:
Title
Percentage of Participants With Hb Response During the First 24 Weeks of Treatment
Description
Hb response was defined as: Hb ≥ 11.0 g/dL and Hb increase from baseline by ≥ 1.0 g/dL for participants with baseline Hb > 8.0 g/dL; or Hb increase from baseline by ≥ 2.0 g/dL, for participants with baseline Hb ≤ 8.0 g/dL at 2 consecutive visits (with available data) separated at least 5 days during the first 24 weeks of treatment without having received rescue therapy (red blood cell [RBC] transfusion, erythropoietin analogue, or intravenous [IV] iron) prior to Hb response. The percentage of participants with an Hb response during the first 24 weeks of treatment is presented.
Time Frame
Baseline (Day 1, Week 0) up to Week 24.
Title
Mean Change From Baseline in Hb Averaged Over Week 28 to Week 52 in Participants With Baseline High Sensitivity C-Reactive Protein (hsCRP) Greater Than the Upper Limit of Normal (ULN)
Description
Baseline hsCRP was quantified from stored biomarker samples obtained at randomization. Baseline Hb was defined as the mean of the last 3 central laboratory Hb values from the screening and randomization visits. Mean change in Hb from baseline to mean value during Week 28 to Week 52 was analyzed using a MAR based multiple imputation ANCOVA model with baseline Hb, baseline eGFR, CV history, geographic region and treatment group as fixed effect covariates. The adjusted LS mean estimates of change from baseline in participants with baseline hsCRP >ULN to mean during Week 28 to Week 52 are presented.
Time Frame
Baseline (Day 1, Week 0) and Week 28 to Week 52.
Title
Proportion of Total Time of Interpolated Hb Values Greater Than or Equal To 10 g/dL From Week 28 to Week 52
Description
Proportion of total time of interpolated Hb values ≥10 g/dL was calculated as the time the linearly interpolated curve between measurements ≥10 g/dL divided by the time between measurements from Week 28 to Week 52. Proportion of total time was analyzed using an ANCOVA model with baseline Hb and baseline eGFR as covariates, and CV history, geographic region and treatment group as fixed effects. The adjusted LS mean estimates of change from Week 28 to Week 52 are presented.
Time Frame
Week 28 up to Week 52.
Title
Proportion of Total Time of Interpolated Hb Values Within the Interval of 10 to 12 g/dL From Week 28 to Week 52
Description
Proportion of total time of interpolated Hb values within the interval of 10 to 12 g/dL was calculated as the time the linearly interpolated curve between measurements were within 10 to 12 g/dL divided by the time between measurements from Week 28 to Week 52. Proportion of total time was analyzed using an ANCOVA model with baseline Hb and baseline eGFR as covariates, and CV history, geographic region and treatment group as fixed effects. The adjusted LS mean estimates of change from Week 28 to Week 52 are presented.
Time Frame
Week 28 up to Week 52.
Title
Mean Change in Low-Density Lipoprotein (LDL) Cholesterol From Baseline to Week 24
Description
Baseline LDL was defined as the last result obtained prior to randomization. Mean changes in LDL cholesterol from baseline to Week 24 was analyzed using an ANCOVA model with baseline LDL, baseline Hb and baseline eGFR as covariates, and CV history, geographic region and treatment group as fixed effects. The adjusted LS mean estimates of change from baseline to Week 24 are presented.
Time Frame
Baseline (Day 1, Week 0) and Week 24
Title
Time-To-First Instance of Receiving IV Iron, RBC Transfusion or Erythropoietin Analogue as Rescue Therapy
Description
Time-to-first rescue therapy (IV iron, RBC transfusion or erythropoietin analogue) was calculated as (date of first rescue therapy, or date of censoring if no rescue therapy was taken) minus (date of first dose of IP) +1. Event rate was calculated as (number of participants with event) divided by (the total number of days at risk for event across all participants in given group divided by 365.25) multiplied by 100. The event rate is presented for participants with events.
Time Frame
Baseline (Day1, Week 0) up to End of Study (EOS) visit (4 weeks after the treatment period) (or up to date of first rescue therapy), with treatment duration up to 4 years.
Title
Time-To-First Instance of Receiving a RBC Transfusion As Rescue Therapy
Description
Time-to-first RBC rescue therapy was calculated as (date of first RBC rescue therapy, or date of censoring if no rescue therapy was taken) minus (date of first dose of IP) +1. Event rate was calculated as (number of participants with event) divided by (the total number of days at risk for event across all participants in given group divided by 365.25) multiplied by 100. The event rate is presented for participants with events.
Time Frame
Baseline (Day1, Week 0) up to EOS visit (4 weeks after the treatment period) (or up to date of first RBC rescue therapy), with treatment duration up to 4 years.
Title
Mean Change From Baseline in Short Form 36 (SF-36) Vitality Sub-Score From Week 12 to Week 28
Description
SF-36 is a Quality of Life (QoL) scale comprising 8 domains of health status: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role Emotional and Mental Health. Each domain score is on a scale from 0-100 (worst health possible to best health possible); higher scores indicate better health status. Mean change in SF-36 Vitality sub-score from baseline to mean from Week 12 to Week 28 was analyzed using a mixed model for repeated measures (MMRM) with terms for baseline score, treatment group, baseline Hb, baseline eGFR, CV history, geographic region, visit and treatment-by-visit interaction as fixed effects and participant as random effect. The adjusted LS mean estimates of change from baseline to mean score from Week 12 to Week 28 are presented.
Time Frame
Baseline (Day 1, Week 0) and Week 12 to Week 28.
Title
Annual Rate of eGFR Change From Baseline Prior to the Initiation of Dialysis or Kidney Transplant
Description
Baseline eGFR was defined as the mean of all available central laboratory values prior to or at randomization. Rate of change in eGFR from baseline during the entire treatment period (in millilitres/minute/1.73 meters squared/years [mL/min/1.73m^2/years]) was estimated using a random effects model using all post-baseline eGFR values prior to initiation of dialysis/transplant. Baseline eGFR, baseline Hb, geographic region, CV history, treatment group and post-baseline eGFR measurement time were used as fixed effects and participant and time (years) as random effects, ie, random intercept and slope.
Time Frame
Baseline (Day1, Week 0) up to EOS visit (4 weeks after the treatment period), with treatment duration up to 4 years.
Title
Mean Change From Baseline in SF-36 Physical Functioning Sub-Score From Week 12 to Week 28
Description
SF-36 is a QoL scale comprising 8 domains of health status: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role Emotional and Mental Health. Each domain score is on a scale from 0-100 (worst health possible to best health possible); higher scores indicate better health status. Mean change in SF-36 Physical Functioning sub-score from baseline to mean from Week 12 to Week 28 was analyzed using a MMRM with terms for baseline score, treatment group, baseline Hb, baseline eGFR, CV history, geographic region, visit and treatment-by-visit interaction as fixed effects and participant as random effect. The adjusted LS mean estimates of change from baseline to mean score from Week 12 to Week 28 are presented.
Time Frame
Baseline (Day 1, Week 0) and Week 12 to Week 28.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
130 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Provision of informed consent prior to any study specific procedures. Age ≥18 years at screening visit 1 eGFR <60 mL/min/1.73 m2, (calculated by central lab) corresponding to stage 3, 4 or 5CKD according to the Kidney Disease Outcomes Quality Initiative (KDOQI), not receiving dialysis Mean of 2 most recent central laboratory Hb values during the screening period, obtained at least 7 days apart, must be <10.0 g/dL Ferritin ≥50 ng/mL at randomization (obtained from screening visit) TSAT ≥15 % at randomization (obtained from screening visit) Serum folate level ≥ lower limit of normal (LLN) at randomization (obtained from screening visit) Serum vitamin B12 level ≥LLN at randomization (obtained from screening visit) Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3 x upper limit of normal (ULN) and total bilirubin (Tbili) ≤1.5 x ULN at randomization (obtained from screening visit) Body weight 45 to 160 kg Exclusion Criteria: Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site) Previous randomization in the present study Any erythropoietin analogue treatment within 6 weeks of randomization New York Heart Association Class III or IV congestive heart failure at enrollment Myocardial infarction (MI), acute coronary syndrome, stroke, seizure or a thrombotic/thromboembolic event (e.g., deep vein thrombosis or pulmonary embolism) within 12 weeks prior to randomization History of chronic liver disease (e.g., chronic infectious hepatitis, chronic auto- immune liver disease, cirrhosis or fibrosis of the liver) Known hereditary hematologic disease such as thalassemia, sickle cell anemia, a history of pure red cell aplasia or other known causes for anemia other than CKD Known and untreated retinal vein occlusion or known and untreated proliferative diabetic retinopathy (risk for retinal vein thrombosis) Diagnosis or suspicion (e.g. complex kidney cyst of Bosniak Category IIF, III or IV) of renal cell carcinoma on renal ultrasound (or other imaging procedure e.g. CT scan or MRI) conducted at screening or within 12 weeks prior to randomization Systolic BP ≥160 mmHg or diastolic BP ≥95 mmHg (confirmed by repeated measurement), within 2 weeks prior to randomization. Patients may be rescreened once BP controlled History of prostate cancer, breast cancer or any other malignancy, except the following: cancers determined to be cured or in remission for ≥5 years, curatively resected basal cell or squamous cell skin cancers, cervical cancer in situ, or resected colonic polyps Positive for any of the following: human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) or anti-hepatitis C virus antibody (anti-HCV Ab) Chronic inflammatory diseases such as rheumatoid arthritis, systemic lupus erythematosus (SLE), ankylosing spondylitis, psoriatic arthritis or inflammatory bowel disease that is determined to be the principal cause of anemia Known hemosiderosis, hemochromatosis or hypercoagulable condition Any prior organ transplant or a scheduled organ transplantation date Any red blood cell transfusion (RBC) during the screening period Any current condition leading to active significant blood loss Any treatment with roxadustat or a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) Has received another new chemical entity (defined as a compound which has not been approved for marketing) or has participated in any other clinical study that included drug treatment within at least 1 month of the first administration of IP in this study. (Note: patients consented and screened, but not randomized in this study or a previous study are not excluded) History of alcohol or drug abuse within 2 years prior to randomization Females of childbearing potential, unless using contraception as detailed in the protocol or sexual abstinence Pregnant or breastfeeding females Known allergy to the investigational product or any of its ingredients Any medical condition, including active, clinically significant infection, that in the opinion of the investigator or Sponsor may pose a safety risk to a patient in this study, which may confound efficacy or safety assessment or may interfere with study participation
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Steven Fishbane, MD
Organizational Affiliation
Chief Division of Kidney Diseases and Hypertension, North Shore University Hospital, Great Neck, NY, USA
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Mark Houser, MD
Organizational Affiliation
AZ R&D Gaithersburg, USA
Official's Role
Study Director
Facility Information:
Facility Name
Research Site
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35209
Country
United States
Facility Name
Research Site
City
Huntsville
State/Province
Alabama
ZIP/Postal Code
35805
Country
United States
Facility Name
Research Site
City
Phoenix
State/Province
Arizona
ZIP/Postal Code
85027
Country
United States
Facility Name
Research Site
City
Bakersfield
State/Province
California
ZIP/Postal Code
93309
Country
United States
Facility Name
Research Site
City
El Centro
State/Province
California
ZIP/Postal Code
92243
Country
United States
Facility Name
Research Site
City
Escondido
State/Province
California
ZIP/Postal Code
92025
Country
United States
Facility Name
Research Site
City
Glendale
State/Province
California
ZIP/Postal Code
91204
Country
United States
Facility Name
Research Site
City
Long Beach
State/Province
California
ZIP/Postal Code
90806
Country
United States
Facility Name
Research Site
City
Long Beach
State/Province
California
ZIP/Postal Code
90807
Country
United States
Facility Name
Research Site
City
Los Angeles
State/Province
California
ZIP/Postal Code
90022
Country
United States
Facility Name
Research Site
City
Los Angeles
State/Province
California
ZIP/Postal Code
90095
Country
United States
Facility Name
Research Site
City
Lynwood
State/Province
California
ZIP/Postal Code
90262
Country
United States
Facility Name
Research Site
City
National City
State/Province
California
ZIP/Postal Code
91950
Country
United States
Facility Name
Research Site
City
Northridge
State/Province
California
ZIP/Postal Code
91324
Country
United States
Facility Name
Research Site
City
Orange
State/Province
California
ZIP/Postal Code
92868
Country
United States
Facility Name
Research Site
City
Sacramento
State/Province
California
ZIP/Postal Code
95825
Country
United States
Facility Name
Research Site
City
Sacramento
State/Province
California
ZIP/Postal Code
95831
Country
United States
Facility Name
Research Site
City
San Diego
State/Province
California
ZIP/Postal Code
92103
Country
United States
Facility Name
Research Site
City
San Dimas
State/Province
California
ZIP/Postal Code
91773
Country
United States
Facility Name
Research Site
City
San Francisco
State/Province
California
ZIP/Postal Code
94110
Country
United States
Facility Name
Research Site
City
San Luis Obispo
State/Province
California
ZIP/Postal Code
93401
Country
United States
Facility Name
Research Site
City
Upland
State/Province
California
ZIP/Postal Code
91786
Country
United States
Facility Name
Research Site
City
Arvada
State/Province
Colorado
ZIP/Postal Code
80002
Country
United States
Facility Name
Research Site
City
Waterbury
State/Province
Connecticut
ZIP/Postal Code
06708
Country
United States
Facility Name
Research Site
City
Aventura
State/Province
Florida
ZIP/Postal Code
33180
Country
United States
Facility Name
Research Site
City
Coral Gables
State/Province
Florida
ZIP/Postal Code
33134
Country
United States
Facility Name
Research Site
City
Coral Springs
State/Province
Florida
ZIP/Postal Code
33071
Country
United States
Facility Name
Research Site
City
Edgewater
State/Province
Florida
ZIP/Postal Code
32132
Country
United States
Facility Name
Research Site
City
Hollywood
State/Province
Florida
ZIP/Postal Code
33021
Country
United States
Facility Name
Research Site
City
Kissimmee
State/Province
Florida
ZIP/Postal Code
34741
Country
United States
Facility Name
Research Site
City
Lauderdale Lakes
State/Province
Florida
ZIP/Postal Code
33313
Country
United States
Facility Name
Research Site
City
Miami
State/Province
Florida
ZIP/Postal Code
33126
Country
United States
Facility Name
Research Site
City
Miami
State/Province
Florida
ZIP/Postal Code
33130
Country
United States
Facility Name
Research Site
City
Miami
State/Province
Florida
ZIP/Postal Code
33133
Country
United States
Facility Name
Research Site
City
Miami
State/Province
Florida
ZIP/Postal Code
33145
Country
United States
Facility Name
Research Site
City
Miami
State/Province
Florida
ZIP/Postal Code
33150
Country
United States
Facility Name
Research Site
City
Miami
State/Province
Florida
ZIP/Postal Code
33165
Country
United States
Facility Name
Research Site
City
Miami
State/Province
Florida
ZIP/Postal Code
33169
Country
United States
Facility Name
Research Site
City
Miami
State/Province
Florida
ZIP/Postal Code
33173
Country
United States
Facility Name
Research Site
City
Port Charlotte
State/Province
Florida
ZIP/Postal Code
33952
Country
United States
Facility Name
Research Site
City
Tampa
State/Province
Florida
ZIP/Postal Code
33607
Country
United States
Facility Name
Research Site
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30342
Country
United States
Facility Name
Research Site
City
Columbus
State/Province
Georgia
ZIP/Postal Code
31901
Country
United States
Facility Name
Research Site
City
Columbus
State/Province
Georgia
ZIP/Postal Code
31904
Country
United States
Facility Name
Research Site
City
Joliet
State/Province
Illinois
ZIP/Postal Code
60435
Country
United States
Facility Name
Research Site
City
La Grange
State/Province
Illinois
ZIP/Postal Code
60525
Country
United States
Facility Name
Research Site
City
Metairie
State/Province
Louisiana
ZIP/Postal Code
70006
Country
United States
Facility Name
Research Site
City
Shreveport
State/Province
Louisiana
ZIP/Postal Code
71101
Country
United States
Facility Name
Research Site
City
Rockport
State/Province
Maine
ZIP/Postal Code
04856
Country
United States
Facility Name
Research Site
City
Greenbelt
State/Province
Maryland
ZIP/Postal Code
20770
Country
United States
Facility Name
Research Site
City
Rockville
State/Province
Maryland
ZIP/Postal Code
20852
Country
United States
Facility Name
Research Site
City
Port Huron
State/Province
Michigan
ZIP/Postal Code
48060
Country
United States
Facility Name
Research Site
City
Gulfport
State/Province
Mississippi
ZIP/Postal Code
39501
Country
United States
Facility Name
Research Site
City
Kansas City
State/Province
Missouri
ZIP/Postal Code
64111
Country
United States
Facility Name
Research Site
City
Omaha
State/Province
Nebraska
ZIP/Postal Code
68124
Country
United States
Facility Name
Research Site
City
Las Vegas
State/Province
Nevada
ZIP/Postal Code
89106
Country
United States
Facility Name
Research Site
City
Las Vegas
State/Province
Nevada
ZIP/Postal Code
89128
Country
United States
Facility Name
Research Site
City
Reno
State/Province
Nevada
ZIP/Postal Code
89511
Country
United States
Facility Name
Research Site
City
Rochester
State/Province
New Hampshire
ZIP/Postal Code
03867
Country
United States
Facility Name
Research Site
City
Flushing
State/Province
New York
ZIP/Postal Code
11355
Country
United States
Facility Name
Research Site
City
Great Neck
State/Province
New York
ZIP/Postal Code
11021
Country
United States
Facility Name
Research Site
City
Charlotte
State/Province
North Carolina
ZIP/Postal Code
28207
Country
United States
Facility Name
Research Site
City
High Point
State/Province
North Carolina
ZIP/Postal Code
27262
Country
United States
Facility Name
Research Site
City
Jacksonville
State/Province
North Carolina
ZIP/Postal Code
28546
Country
United States
Facility Name
Research Site
City
New Bern
State/Province
North Carolina
ZIP/Postal Code
28562
Country
United States
Facility Name
Research Site
City
Wilmington
State/Province
North Carolina
ZIP/Postal Code
28401
Country
United States
Facility Name
Research Site
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45206
Country
United States
Facility Name
Research Site
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45220
Country
United States
Facility Name
Research Site
City
Columbus
State/Province
Ohio
ZIP/Postal Code
43215
Country
United States
Facility Name
Research Site
City
Oklahoma City
State/Province
Oklahoma
ZIP/Postal Code
73116
Country
United States
Facility Name
Research Site
City
Bethlehem
State/Province
Pennsylvania
ZIP/Postal Code
18017
Country
United States
Facility Name
Research Site
City
Lansdale
State/Province
Pennsylvania
ZIP/Postal Code
19446
Country
United States
Facility Name
Research Site
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19104
Country
United States
Facility Name
Research Site
City
Uniontown
State/Province
Pennsylvania
ZIP/Postal Code
15401
Country
United States
Facility Name
Research Site
City
Providence
State/Province
Rhode Island
ZIP/Postal Code
02908
Country
United States
Facility Name
Research Site
City
Providence
State/Province
Rhode Island
ZIP/Postal Code
02915
Country
United States
Facility Name
Research Site
City
Columbia
State/Province
South Carolina
ZIP/Postal Code
29203
Country
United States
Facility Name
Research Site
City
Knoxville
State/Province
Tennessee
ZIP/Postal Code
37923
Country
United States
Facility Name
Research Site
City
Corpus Christi
State/Province
Texas
ZIP/Postal Code
78404
Country
United States
Facility Name
Research Site
City
Cypress
State/Province
Texas
ZIP/Postal Code
77429
Country
United States
Facility Name
Research Site
City
Dallas
State/Province
Texas
ZIP/Postal Code
75231
Country
United States
Facility Name
Research Site
City
Houston
State/Province
Texas
ZIP/Postal Code
77004
Country
United States
Facility Name
Research Site
City
Houston
State/Province
Texas
ZIP/Postal Code
77024
Country
United States
Facility Name
Research Site
City
Houston
State/Province
Texas
ZIP/Postal Code
77074
Country
United States
Facility Name
Research Site
City
Houston
State/Province
Texas
ZIP/Postal Code
77084
Country
United States
Facility Name
Research Site
City
Houston
State/Province
Texas
ZIP/Postal Code
77090
Country
United States
Facility Name
Research Site
City
Houston
State/Province
Texas
ZIP/Postal Code
77099
Country
United States
Facility Name
Research Site
City
Lufkin
State/Province
Texas
ZIP/Postal Code
75904
Country
United States
Facility Name
Research Site
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78207
Country
United States
Facility Name
Research Site
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78212
Country
United States
Facility Name
Research Site
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78229
Country
United States
Facility Name
Research Site
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78258
Country
United States
Facility Name
Research Site
City
Saint George
State/Province
Utah
ZIP/Postal Code
84790
Country
United States
Facility Name
Research Site
City
Salt Lake City
State/Province
Utah
ZIP/Postal Code
84115
Country
United States
Facility Name
Research Site
City
Norfolk
State/Province
Virginia
ZIP/Postal Code
23507
Country
United States
Facility Name
Research Site
City
Salem
State/Province
Virginia
ZIP/Postal Code
24153
Country
United States
Facility Name
Research Site
City
Woodbridge
State/Province
Virginia
ZIP/Postal Code
22191
Country
United States
Facility Name
Research Site
City
Caba
ZIP/Postal Code
C1012AAR
Country
Argentina
Facility Name
Research Site
City
Caba
ZIP/Postal Code
C1440AAD
Country
Argentina
Facility Name
Research Site
City
Capital Federal
ZIP/Postal Code
C1425AGC
Country
Argentina
Facility Name
Research Site
City
Ciudad Autónoma de Bs. As.
ZIP/Postal Code
C1199ABB
Country
Argentina
Facility Name
Research Site
City
Ciudadela
ZIP/Postal Code
1702
Country
Argentina
Facility Name
Research Site
City
La Plata
ZIP/Postal Code
1900
Country
Argentina
Facility Name
Research Site
City
La Plata
ZIP/Postal Code
C1427ARO
Country
Argentina
Facility Name
Research Site
City
Lanus
ZIP/Postal Code
B1824KAJ
Country
Argentina
Facility Name
Research Site
City
Mar del Plata
ZIP/Postal Code
7600
Country
Argentina
Facility Name
Research Site
City
Munro
ZIP/Postal Code
1605
Country
Argentina
Facility Name
Research Site
City
Ramos Mejía
ZIP/Postal Code
B1704ETD
Country
Argentina
Facility Name
Research Site
City
Rosario
ZIP/Postal Code
2000
Country
Argentina
Facility Name
Research Site
City
Rosario
ZIP/Postal Code
S2000DNM
Country
Argentina
Facility Name
Research Site
City
San Isidro
ZIP/Postal Code
B1642DCD
Country
Argentina
Facility Name
Research Site
City
San Miguel de Tucuman
ZIP/Postal Code
4000
Country
Argentina
Facility Name
Research Site
City
Santa Rosa
ZIP/Postal Code
6300
Country
Argentina
Facility Name
Research Site
City
Curitiba
ZIP/Postal Code
80230-130
Country
Brazil
Facility Name
Research Site
City
Curitiba
ZIP/Postal Code
80440-020
Country
Brazil
Facility Name
Research Site
City
Curitiba
ZIP/Postal Code
80810-040
Country
Brazil
Facility Name
Research Site
City
Feira de Santana
ZIP/Postal Code
44001-584
Country
Brazil
Facility Name
Research Site
City
Fortaleza
ZIP/Postal Code
60115282
Country
Brazil
Facility Name
Research Site
City
Fortaleza
ZIP/Postal Code
60430-350
Country
Brazil
Facility Name
Research Site
City
Fortaleza
ZIP/Postal Code
60430-370
Country
Brazil
Facility Name
Research Site
City
Goiânia
ZIP/Postal Code
74043-011
Country
Brazil
Facility Name
Research Site
City
Joinville
Country
Brazil
Facility Name
Research Site
City
Juiz de Fora
ZIP/Postal Code
36036-330
Country
Brazil
Facility Name
Research Site
City
Maringa
ZIP/Postal Code
87083-240
Country
Brazil
Facility Name
Research Site
City
Porto Alegre
ZIP/Postal Code
90035-003
Country
Brazil
Facility Name
Research Site
City
Porto Alegre
ZIP/Postal Code
90160-093
Country
Brazil
Facility Name
Research Site
City
Porto Alegre
ZIP/Postal Code
90610-000
Country
Brazil
Facility Name
Research Site
City
Sao Bernardo do Campo
ZIP/Postal Code
09715090
Country
Brazil
Facility Name
Research Site
City
Sao Paulo
ZIP/Postal Code
01323-030
Country
Brazil
Facility Name
Research Site
City
Sao Paulo
ZIP/Postal Code
05403-000
Country
Brazil
Facility Name
Research Site
City
Sao Paulo
ZIP/Postal Code
08270-070
Country
Brazil
Facility Name
Research Site
City
São Paulo
ZIP/Postal Code
04039-000
Country
Brazil
Facility Name
Research Site
City
Botevgrad
ZIP/Postal Code
2140
Country
Bulgaria
Facility Name
Research Site
City
Dupnitsa
ZIP/Postal Code
2600
Country
Bulgaria
Facility Name
Research Site
City
Gotse Delchev
ZIP/Postal Code
2900
Country
Bulgaria
Facility Name
Research Site
City
Haskovo
ZIP/Postal Code
6300
Country
Bulgaria
Facility Name
Research Site
City
Kozloduy
ZIP/Postal Code
3320
Country
Bulgaria
Facility Name
Research Site
City
Samokov
ZIP/Postal Code
2000
Country
Bulgaria
Facility Name
Research Site
City
Sandanski
ZIP/Postal Code
2800
Country
Bulgaria
Facility Name
Research Site
City
Silistra
ZIP/Postal Code
7500
Country
Bulgaria
Facility Name
Research Site
City
Sliven
ZIP/Postal Code
8800
Country
Bulgaria
Facility Name
Research Site
City
Smolyan
ZIP/Postal Code
3700
Country
Bulgaria
Facility Name
Research Site
City
Yambol
ZIP/Postal Code
8600
Country
Bulgaria
Facility Name
Research Site
City
Edmonton
State/Province
Alberta
ZIP/Postal Code
T6G 2B7
Country
Canada
Facility Name
Research Site
City
Kamloops
State/Province
British Columbia
ZIP/Postal Code
V2C 2T1
Country
Canada
Facility Name
Research Site
City
New Westminster
State/Province
British Columbia
ZIP/Postal Code
V3L 0A6
Country
Canada
Facility Name
Research Site
City
Winnipeg
State/Province
Manitoba
ZIP/Postal Code
R2V 3M3
Country
Canada
Facility Name
Research Site
City
Saint John
State/Province
New Brunswick
ZIP/Postal Code
E2L 4L2
Country
Canada
Facility Name
Research Site
City
Sydney
State/Province
Nova Scotia
ZIP/Postal Code
B1P 1P3
Country
Canada
Facility Name
Research Site
City
Brampton
State/Province
Ontario
ZIP/Postal Code
L6R 3J7
Country
Canada
Facility Name
Research Site
City
Brampton
State/Province
Ontario
ZIP/Postal Code
L6T 0G1
Country
Canada
Facility Name
Research Site
City
Kitchener
State/Province
Ontario
ZIP/Postal Code
N2H 5Z8
Country
Canada
Facility Name
Research Site
City
London
State/Province
Ontario
ZIP/Postal Code
N6A 5A5
Country
Canada
Facility Name
Research Site
City
Oakville
State/Province
Ontario
ZIP/Postal Code
L6K 3V3
Country
Canada
Facility Name
Research Site
City
Scarborough
State/Province
Ontario
ZIP/Postal Code
M1H 3G4
Country
Canada
Facility Name
Research Site
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M4C 5T2
Country
Canada
Facility Name
Research Site
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M4S 1Y2
Country
Canada
Facility Name
Research Site
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5C 2T2
Country
Canada
Facility Name
Research Site
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M9N 1N8
Country
Canada
Facility Name
Research Site
City
Whitby
State/Province
Ontario
ZIP/Postal Code
L1N 5T2
Country
Canada
Facility Name
Research Site
City
Gatineau
State/Province
Quebec
ZIP/Postal Code
J8Y 6S8
Country
Canada
Facility Name
Research Site
City
Greenfield Park
State/Province
Quebec
ZIP/Postal Code
J4V 2H1
Country
Canada
Facility Name
Research Site
City
Montreal
State/Province
Quebec
ZIP/Postal Code
H1T 2M4
Country
Canada
Facility Name
Research Site
City
Montreal
State/Province
Quebec
ZIP/Postal Code
H4J 1C5
Country
Canada
Facility Name
Research Site
City
Quebec
ZIP/Postal Code
G1R 2J6
Country
Canada
Facility Name
Research Site
City
Cali
ZIP/Postal Code
760032
Country
Colombia
Facility Name
Research Site
City
Chia
ZIP/Postal Code
250008
Country
Colombia
Facility Name
Research Site
City
Medellin
ZIP/Postal Code
5001000
Country
Colombia
Facility Name
Research Site
City
Zipaquira
ZIP/Postal Code
250258
Country
Colombia
Facility Name
Research Site
City
Brno
ZIP/Postal Code
625 00
Country
Czechia
Facility Name
Research Site
City
Havlickuv Brod
ZIP/Postal Code
580 22
Country
Czechia
Facility Name
Research Site
City
Ivancice
ZIP/Postal Code
664 91
Country
Czechia
Facility Name
Research Site
City
Praha
ZIP/Postal Code
190 61
Country
Czechia
Facility Name
Research Site
City
Rychnov nad Kneznou
ZIP/Postal Code
516 01
Country
Czechia
Facility Name
Research Site
City
Slany
ZIP/Postal Code
274 01
Country
Czechia
Facility Name
Research Site
City
Slavkov u Brna
Country
Czechia
Facility Name
Research Site
City
Sumperk
ZIP/Postal Code
787 01
Country
Czechia
Facility Name
Research Site
City
Usti nad Labem
ZIP/Postal Code
401 13
Country
Czechia
Facility Name
Research Site
City
Usti nad Orlici
ZIP/Postal Code
562 18
Country
Czechia
Facility Name
Research Site
City
Berlin
ZIP/Postal Code
10117
Country
Germany
Facility Name
Research Site
City
Cloppenburg
ZIP/Postal Code
49661
Country
Germany
Facility Name
Research Site
City
Köln
ZIP/Postal Code
50937
Country
Germany
Facility Name
Research Site
City
Ajka
ZIP/Postal Code
8400
Country
Hungary
Facility Name
Research Site
City
Budapest
ZIP/Postal Code
1096
Country
Hungary
Facility Name
Research Site
City
Budapest
ZIP/Postal Code
1134
Country
Hungary
Facility Name
Research Site
City
Gyula
ZIP/Postal Code
5700
Country
Hungary
Facility Name
Research Site
City
Hatvan
ZIP/Postal Code
3000
Country
Hungary
Facility Name
Research Site
City
Kecskemét
ZIP/Postal Code
6000
Country
Hungary
Facility Name
Research Site
City
Nyíregyháza
ZIP/Postal Code
4400
Country
Hungary
Facility Name
Research Site
City
Polgár
ZIP/Postal Code
4090
Country
Hungary
Facility Name
Research Site
City
Pécs
ZIP/Postal Code
7623
Country
Hungary
Facility Name
Research Site
City
Salgótarján
ZIP/Postal Code
3100
Country
Hungary
Facility Name
Research Site
City
Siófok
ZIP/Postal Code
8600
Country
Hungary
Facility Name
Research Site
City
Tatabánya
ZIP/Postal Code
2800
Country
Hungary
Facility Name
Research Site
City
Velence
ZIP/Postal Code
2481
Country
Hungary
Facility Name
Research Site
City
Ahmedabad
ZIP/Postal Code
380016
Country
India
Facility Name
Research Site
City
Bangalore
ZIP/Postal Code
560052
Country
India
Facility Name
Research Site
City
Bangalore
ZIP/Postal Code
560068
Country
India
Facility Name
Research Site
City
Bangalore
ZIP/Postal Code
560070
Country
India
Facility Name
Research Site
City
Chennai
ZIP/Postal Code
600006
Country
India
Facility Name
Research Site
City
Ghaziabad NCR
ZIP/Postal Code
201012
Country
India
Facility Name
Research Site
City
Hyderabad
ZIP/Postal Code
500018
Country
India
Facility Name
Research Site
City
Hyderabad
ZIP/Postal Code
500072
Country
India
Facility Name
Research Site
City
Kolkatta
ZIP/Postal Code
700027
Country
India
Facility Name
Research Site
City
Lucknow
ZIP/Postal Code
226003
Country
India
Facility Name
Research Site
City
Maharashtra
ZIP/Postal Code
411013
Country
India
Facility Name
Research Site
City
Mumbai
ZIP/Postal Code
400008
Country
India
Facility Name
Research Site
City
Mysore
ZIP/Postal Code
570004
Country
India
Facility Name
Research Site
City
Nagpur
ZIP/Postal Code
420012
Country
India
Facility Name
Research Site
City
Nagpur
ZIP/Postal Code
440003
Country
India
Facility Name
Research Site
City
Nagpur
ZIP/Postal Code
440012
Country
India
Facility Name
Research Site
City
New Delhi
ZIP/Postal Code
110017
Country
India
Facility Name
Research Site
City
New Delhi
ZIP/Postal Code
110060
Country
India
Facility Name
Research Site
City
Pune
ZIP/Postal Code
411001
Country
India
Facility Name
Research Site
City
Vijayawada
ZIP/Postal Code
520 008
Country
India
Facility Name
Research Site
City
Vijayawada
ZIP/Postal Code
522002
Country
India
Facility Name
Research Site
City
Vishakhapatnam
ZIP/Postal Code
530002
Country
India
Facility Name
Research Site
City
Ansan-si
ZIP/Postal Code
15355
Country
Korea, Republic of
Facility Name
Research Site
City
Busan
ZIP/Postal Code
49241
Country
Korea, Republic of
Facility Name
Research Site
City
Daegu
ZIP/Postal Code
42415
Country
Korea, Republic of
Facility Name
Research Site
City
Daejeon
ZIP/Postal Code
35015
Country
Korea, Republic of
Facility Name
Research Site
City
Goyang-si
ZIP/Postal Code
10380
Country
Korea, Republic of
Facility Name
Research Site
City
Goyang-si
ZIP/Postal Code
10444
Country
Korea, Republic of
Facility Name
Research Site
City
Incheon
ZIP/Postal Code
403-720
Country
Korea, Republic of
Facility Name
Research Site
City
Seongnam-si
ZIP/Postal Code
13620
Country
Korea, Republic of
Facility Name
Research Site
City
Seoul
ZIP/Postal Code
03312
Country
Korea, Republic of
Facility Name
Research Site
City
Seoul
ZIP/Postal Code
06273
Country
Korea, Republic of
Facility Name
Research Site
City
Seoul
ZIP/Postal Code
08308
Country
Korea, Republic of
Facility Name
Research Site
City
Seoul
ZIP/Postal Code
139-711
Country
Korea, Republic of
Facility Name
Research Site
City
Uijeongbu-si
ZIP/Postal Code
11765
Country
Korea, Republic of
Facility Name
Research Site
City
George Town
ZIP/Postal Code
10990
Country
Malaysia
Facility Name
Research Site
City
Kubang Kerian
ZIP/Postal Code
16150
Country
Malaysia
Facility Name
Research Site
City
Putrajaya
ZIP/Postal Code
62250
Country
Malaysia
Facility Name
Research Site
City
Taiping
ZIP/Postal Code
34000
Country
Malaysia
Facility Name
Research Site
City
Aguascalientes
ZIP/Postal Code
20219
Country
Mexico
Facility Name
Research Site
City
Culiacán
ZIP/Postal Code
80230
Country
Mexico
Facility Name
Research Site
City
Guadalajara
ZIP/Postal Code
44670
Country
Mexico
Facility Name
Research Site
City
Guadalajara
ZIP/Postal Code
44676
Country
Mexico
Facility Name
Research Site
City
Minatitlán
ZIP/Postal Code
96730
Country
Mexico
Facility Name
Research Site
City
México
ZIP/Postal Code
06726
Country
Mexico
Facility Name
Research Site
City
Veracruz
ZIP/Postal Code
91900
Country
Mexico
Facility Name
Research Site
City
Xalapa
ZIP/Postal Code
91020
Country
Mexico
Facility Name
Research Site
City
Bellavista
ZIP/Postal Code
CALLAO 2
Country
Peru
Facility Name
Research Site
City
Ica
Country
Peru
Facility Name
Research Site
City
Lima
ZIP/Postal Code
14
Country
Peru
Facility Name
Research Site
City
Lima
ZIP/Postal Code
L17
Country
Peru
Facility Name
Research Site
City
Lima
ZIP/Postal Code
LIMA 01
Country
Peru
Facility Name
Research Site
City
Lima
ZIP/Postal Code
LIMA 1
Country
Peru
Facility Name
Research Site
City
Lima
ZIP/Postal Code
LIMA 27
Country
Peru
Facility Name
Research Site
City
Lima
ZIP/Postal Code
LIMA 31
Country
Peru
Facility Name
Research Site
City
Trujillo
ZIP/Postal Code
044
Country
Peru
Facility Name
Research Site
City
Cebu City
ZIP/Postal Code
6000
Country
Philippines
Facility Name
Research Site
City
Iloilo City
ZIP/Postal Code
5000
Country
Philippines
Facility Name
Research Site
City
Iloilo
ZIP/Postal Code
5000
Country
Philippines
Facility Name
Research Site
City
Quezon City
ZIP/Postal Code
1101
Country
Philippines
Facility Name
Research Site
City
Ciechanów
ZIP/Postal Code
06-400
Country
Poland
Facility Name
Research Site
City
Końskie
ZIP/Postal Code
26-200
Country
Poland
Facility Name
Research Site
City
Poznań
ZIP/Postal Code
60-355
Country
Poland
Facility Name
Research Site
City
Sochaczew
ZIP/Postal Code
96-500
Country
Poland
Facility Name
Research Site
City
Tczew
ZIP/Postal Code
83-110
Country
Poland
Facility Name
Research Site
City
Łódź
ZIP/Postal Code
90-141
Country
Poland
Facility Name
Research Site
City
Cidra
ZIP/Postal Code
00739
Country
Puerto Rico
Facility Name
Research Site
City
Rio Grande
ZIP/Postal Code
00745
Country
Puerto Rico
Facility Name
Research Site
City
Rio Piedras
ZIP/Postal Code
00935
Country
Puerto Rico
Facility Name
Research Site
City
San Juan
ZIP/Postal Code
00909
Country
Puerto Rico
Facility Name
Research Site
City
San Juan
ZIP/Postal Code
00917
Country
Puerto Rico
Facility Name
Research Site
City
San Juan
ZIP/Postal Code
00921
Country
Puerto Rico
Facility Name
Research Site
City
San Juan
ZIP/Postal Code
00927
Country
Puerto Rico
Facility Name
Research Site
City
Toa Baja
ZIP/Postal Code
00949
Country
Puerto Rico
Facility Name
Research Site
City
Arad
ZIP/Postal Code
310017
Country
Romania
Facility Name
Research Site
City
Bucuresti
ZIP/Postal Code
010731
Country
Romania
Facility Name
Research Site
City
Bucuresti
ZIP/Postal Code
020475
Country
Romania
Facility Name
Research Site
City
Targu Mures
ZIP/Postal Code
540000
Country
Romania
Facility Name
Research Site
City
Timisoara
ZIP/Postal Code
300736
Country
Romania
Facility Name
Research Site
City
Arkhangelsk
ZIP/Postal Code
163001
Country
Russian Federation
Facility Name
Research Site
City
Barnaul
ZIP/Postal Code
656024
Country
Russian Federation
Facility Name
Research Site
City
Irkutsk
ZIP/Postal Code
664049
Country
Russian Federation
Facility Name
Research Site
City
Izhevsk
ZIP/Postal Code
426035
Country
Russian Federation
Facility Name
Research Site
City
Kemerovo
ZIP/Postal Code
650066
Country
Russian Federation
Facility Name
Research Site
City
Krasnoyarsk
ZIP/Postal Code
660062
Country
Russian Federation
Facility Name
Research Site
City
Moscow
ZIP/Postal Code
105229
Country
Russian Federation
Facility Name
Research Site
City
Moscow
ZIP/Postal Code
109263
Country
Russian Federation
Facility Name
Research Site
City
Moscow
ZIP/Postal Code
129344
Country
Russian Federation
Facility Name
Research Site
City
Nizhniy Novgorod
ZIP/Postal Code
603076
Country
Russian Federation
Facility Name
Research Site
City
Nizhny Novgorod
ZIP/Postal Code
603126
Country
Russian Federation
Facility Name
Research Site
City
Perm
ZIP/Postal Code
614000
Country
Russian Federation
Facility Name
Research Site
City
Ryazan
ZIP/Postal Code
390027
Country
Russian Federation
Facility Name
Research Site
City
Saint Petersburg
ZIP/Postal Code
191015
Country
Russian Federation
Facility Name
Research Site
City
Saint Petersburg
ZIP/Postal Code
194354
Country
Russian Federation
Facility Name
Research Site
City
Saint Petersburg
ZIP/Postal Code
196601
Country
Russian Federation
Facility Name
Research Site
City
Ufa
ZIP/Postal Code
450000
Country
Russian Federation
Facility Name
Research Site
City
Ufa
ZIP/Postal Code
450005
Country
Russian Federation
Facility Name
Research Site
City
Ufa
ZIP/Postal Code
450071
Country
Russian Federation
Facility Name
Research Site
City
Volgograd
ZIP/Postal Code
404120
Country
Russian Federation
Facility Name
Research Site
City
Bratislava
ZIP/Postal Code
82606
Country
Slovakia
Facility Name
Research Site
City
Bratislava
ZIP/Postal Code
831 03
Country
Slovakia
Facility Name
Research Site
City
Kosice
ZIP/Postal Code
04011
Country
Slovakia
Facility Name
Research Site
City
Kralovsky Chlmec
ZIP/Postal Code
077 01
Country
Slovakia
Facility Name
Research Site
City
Nove Zamky
ZIP/Postal Code
940 34
Country
Slovakia
Facility Name
Research Site
City
Zvolen
ZIP/Postal Code
960 01
Country
Slovakia
Facility Name
Research Site
City
Almería
ZIP/Postal Code
04009
Country
Spain
Facility Name
Research Site
City
Málaga
ZIP/Postal Code
29010
Country
Spain
Facility Name
Research Site
City
Santiago de Compostela
ZIP/Postal Code
15706
Country
Spain
Facility Name
Research Site
City
Sevilla
ZIP/Postal Code
41013
Country
Spain
Facility Name
Research Site
City
Valencia
ZIP/Postal Code
46010
Country
Spain
Facility Name
Research Site
City
Valencia
ZIP/Postal Code
46017
Country
Spain
Facility Name
Research Site
City
Valencia
ZIP/Postal Code
46026
Country
Spain
Facility Name
Research Site
City
Kaohsiung City
ZIP/Postal Code
82445
Country
Taiwan
Facility Name
Research Site
City
Keelung
ZIP/Postal Code
20401
Country
Taiwan
Facility Name
Research Site
City
New Taipei
ZIP/Postal Code
220
Country
Taiwan
Facility Name
Research Site
City
New Taipei
ZIP/Postal Code
231
Country
Taiwan
Facility Name
Research Site
City
New Taipei
ZIP/Postal Code
23561
Country
Taiwan
Facility Name
Research Site
City
Taichung
ZIP/Postal Code
402
Country
Taiwan
Facility Name
Research Site
City
Taipei
ZIP/Postal Code
0116
Country
Taiwan
Facility Name
Research Site
City
Taipei
ZIP/Postal Code
10491
Country
Taiwan
Facility Name
Research Site
City
Taipei
Country
Taiwan
Facility Name
Research Site
City
TaoYuan
ZIP/Postal Code
333
Country
Taiwan
Facility Name
Research Site
City
Bangkok
ZIP/Postal Code
10300
Country
Thailand
Facility Name
Research Site
City
Bangkok
ZIP/Postal Code
10330
Country
Thailand
Facility Name
Research Site
City
Bangkok
ZIP/Postal Code
10400
Country
Thailand
Facility Name
Research Site
City
Bangkok
ZIP/Postal Code
10700
Country
Thailand
Facility Name
Research Site
City
Khon Kaen
ZIP/Postal Code
40000
Country
Thailand
Facility Name
Research Site
City
Khon Kaen
ZIP/Postal Code
40002
Country
Thailand
Facility Name
Research Site
City
Adana
ZIP/Postal Code
01330
Country
Turkey
Facility Name
Research Site
City
Ankara
ZIP/Postal Code
06230
Country
Turkey
Facility Name
Research Site
City
Ankara
ZIP/Postal Code
06490
Country
Turkey
Facility Name
Research Site
City
Antalya
Country
Turkey
Facility Name
Research Site
City
Istanbul
ZIP/Postal Code
34093
Country
Turkey
Facility Name
Research Site
City
Istanbul
ZIP/Postal Code
34098
Country
Turkey
Facility Name
Research Site
City
Izmir
ZIP/Postal Code
35040
Country
Turkey
Facility Name
Research Site
City
Chernivtsi
ZIP/Postal Code
58002
Country
Ukraine
Facility Name
Research Site
City
Dnipro
ZIP/Postal Code
49005
Country
Ukraine
Facility Name
Research Site
City
Ivano-Frankivsk
ZIP/Postal Code
76008
Country
Ukraine
Facility Name
Research Site
City
Kharkiv
ZIP/Postal Code
61002
Country
Ukraine
Facility Name
Research Site
City
Kharkiv
ZIP/Postal Code
61039
Country
Ukraine
Facility Name
Research Site
City
Kharkiv
ZIP/Postal Code
61058
Country
Ukraine
Facility Name
Research Site
City
Kharkiv
ZIP/Postal Code
61103
Country
Ukraine
Facility Name
Research Site
City
Khmelnytsky
ZIP/Postal Code
29000
Country
Ukraine
Facility Name
Research Site
City
Kirovograd
ZIP/Postal Code
25006
Country
Ukraine
Facility Name
Research Site
City
Kyiv
ZIP/Postal Code
01601
Country
Ukraine
Facility Name
Research Site
City
Kyiv
ZIP/Postal Code
02125
Country
Ukraine
Facility Name
Research Site
City
Kyiv
ZIP/Postal Code
04050
Country
Ukraine
Facility Name
Research Site
City
Kyiv
ZIP/Postal Code
04107
Country
Ukraine
Facility Name
Research Site
City
Kyiv
ZIP/Postal Code
04114
Country
Ukraine
Facility Name
Research Site
City
Lutsk
ZIP/Postal Code
43005
Country
Ukraine
Facility Name
Research Site
City
Lviv
ZIP/Postal Code
79010
Country
Ukraine
Facility Name
Research Site
City
Odesa
ZIP/Postal Code
65009
Country
Ukraine
Facility Name
Research Site
City
Rivne
ZIP/Postal Code
33027
Country
Ukraine
Facility Name
Research Site
City
Vinnytsia
ZIP/Postal Code
21018
Country
Ukraine
Facility Name
Research Site
City
Vinnytsia
ZIP/Postal Code
21029
Country
Ukraine
Facility Name
Research Site
City
Zaporizhzhya
ZIP/Postal Code
69001
Country
Ukraine
Facility Name
Research Site
City
Zaporizhzhya
ZIP/Postal Code
69068
Country
Ukraine
Facility Name
Research Site
City
Zaporizhzhya
ZIP/Postal Code
69118
Country
Ukraine
Facility Name
Research Site
City
Zaporizhzhya
ZIP/Postal Code
69600
Country
Ukraine
Facility Name
Research Site
City
Can Tho
ZIP/Postal Code
900000
Country
Vietnam
Facility Name
Research Site
City
Hanoi
ZIP/Postal Code
100000
Country
Vietnam
Facility Name
Research Site
City
Ho Chi Minh City
ZIP/Postal Code
700000
Country
Vietnam
Facility Name
Research Site
City
Hochiminh
ZIP/Postal Code
550000
Country
Vietnam
Facility Name
Research Site
City
Hochiminh
ZIP/Postal Code
700000
Country
Vietnam
Facility Name
Research Site
City
Hue
ZIP/Postal Code
530000
Country
Vietnam

12. IPD Sharing Statement

Citations:
PubMed Identifier
36005278
Citation
Natale P, Palmer SC, Jaure A, Hodson EM, Ruospo M, Cooper TE, Hahn D, Saglimbene VM, Craig JC, Strippoli GF. Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease. Cochrane Database Syst Rev. 2022 Aug 25;8(8):CD013751. doi: 10.1002/14651858.CD013751.pub2.
Results Reference
derived
PubMed Identifier
34362786
Citation
Provenzano R, Szczech L, Leong R, Saikali KG, Zhong M, Lee TT, Little DJ, Houser MT, Frison L, Houghton J, Neff TB. Efficacy and Cardiovascular Safety of Roxadustat for Treatment of Anemia in Patients with Non-Dialysis-Dependent CKD: Pooled Results of Three Randomized Clinical Trials. Clin J Am Soc Nephrol. 2021 Aug;16(8):1190-1200. doi: 10.2215/CJN.16191020.
Results Reference
derived
PubMed Identifier
33568383
Citation
Fishbane S, El-Shahawy MA, Pecoits-Filho R, Van BP, Houser MT, Frison L, Little DJ, Guzman NJ, Pergola PE. Roxadustat for Treating Anemia in Patients with CKD Not on Dialysis: Results from a Randomized Phase 3 Study. J Am Soc Nephrol. 2021 Mar;32(3):737-755. doi: 10.1681/ASN.2020081150. Epub 2021 Feb 10.
Results Reference
derived
Links:
URL
https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D5740C00001&amp;attachmentIdentifier=e591fa4d-7259-4500-bf4c-783f4239fab9&amp;fileName=D5740C00001_redacted_CSP_from_PRS.pdf&amp;versionIdentifier=
Description
Related Info
URL
https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D5740C00001&amp;attachmentIdentifier=cf047ffd-547d-4bee-b970-58c377627038&amp;fileName=D5740C00001_SAP-v3_Redacted_28-Sep-2018.pdf&amp;versionIdentifier=
Description
Related Info

Learn more about this trial

Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease (CKD), Not on Dialysis

We'll reach out to this number within 24 hrs